Craig-Hallum Maintains Omnicell(OMCL.US) With Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (MRK) and Omnicell (OMCL)
KeyBanc Maintains Omnicell(OMCL.US) With Hold Rating
Omnicell (OMCL) Receives a Hold From KeyBanc
Omnicell's Strategic Rebranding and Market Outlook: A Hold Recommendation
Craig-Hallum Initiates Omnicell(OMCL.US) With Buy Rating
Piper Sandler Maintains Omnicell(OMCL.US) With Buy Rating, Raises Target Price to $61
Piper Sandler Remains a Buy on Omnicell (OMCL)
Omnicell Analyst Ratings
Craig-Hallum Maintains Omnicell(OMCL.US) With Buy Rating
Omnicell (OMCL) Receives a Buy From Craig-Hallum
Omnicell Price Target Raised to $30.00/Share From $26.00 by Wells Fargo
Wells Fargo Maintains Equal-Weight on Omnicell, Raises Price Target to $30
BofA Securities Maintains Omnicell(OMCL.US) With Buy Rating, Maintains Target Price $44
Craig-Hallum Maintains Omnicell(OMCL.US) With Buy Rating
Omnicell Analyst Ratings
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Alnylam Pharma (ALNY) and Omnicell (OMCL)
BofA Securities Maintains Omnicell(OMCL.US) With Buy Rating, Raises Target Price to $44
Barclays Upgrades Omnicell(OMCL.US) to Hold Rating, Raises Target Price to $39
Craig-Hallum Maintains Omnicell(OMCL.US) With Buy Rating